Media
EndpointsNews
Citrine Medicine To Present at the 2021 WuXi Healthcare Forum and Participate in Two Additional Upcoming Healthcare Conferences
2021-03-16
March 16, 2021 – Cambridge, Mass. and Shanghai, China – Citrine Medicine, a China-based rare disease
therapeutics company, today announced that it will participate in three industry conferences in March,

including a presentation at the 2021 WuXi Healthcare Forum, which will be held from March 15-18, 2021.


Conference details are as follows:
• WuXi Healthcare Forum: Citrine’s management will participate in the CEO Roundtable on March
16 from 6:15-6:45 p.m. PT, and on March 17 from 6:45-7:15 p.m. PT. The discussion will be
accessible live and interactively via a dedicated portal for registered attendees.
• ENDO 2021: Members of Citrine’s management team will attend the Endocrine’s Society
Annual Meeting from March 20-23.

• BIO Europe: Members of Citrine’s management team will attend BIO Europe from March 22-25.


About Citrine Medicine
Citrine Medicine is dedicated to improving the lives of patients with rare and intractable diseases
by making diagnosis and essential treatments available and accessible to those who need them in China.
Our mission is to build the first rare disease ecosystem in China and in doing so, enable people with rare
diseases to live more normal lives. In addition to developing and marketing rare disease drugs, Citrine
aims to establish a patient-centric platform which educates people on rare diseases, trains doctors on
diagnosis and treatment, and helps doctors develop a full disease management protocol. Citrine’s lead
product candidate, Wakix® (pitolisant), is an investigational oral drug in development for the treatment
of narcolepsy and obstructive sleep apnea in China. Citrine has initiated an Investigational New Drug (IND)
submission for pitolisant in the treatment of narcolepsy and expects to complete the IND submission in
the first quarter of 2021. Citrine also recently announced a strategic partnership that will allow the
company exclusive rights to develop, register, and commercialize Alkindi®—the first clinically validated
pediatric treatment for congenital adrenal hyperplasia—in the Greater China market. Citrine is

headquartered in Shanghai and has other offices in Beijing, China and Cambridge, Mass.


For more information, visit www.citrinemed.com


Citrine Medicine Media Contacts:

Sarah Sutton
Finsbury Glover Herring
sarah.sutton@fgh.com
202-337-0808